Astellas Pharma (4503.T) Profit Metrics
Price: $1496.00
Market Cap: $2.68T
Avg Volume: 6.22M
Market Cap: $2.68T
Avg Volume: 6.22M
Country: JP
Industry: Drug Manufacturers - General
Sector: Healthcare
Industry: Drug Manufacturers - General
Sector: Healthcare
Profit Metrics Summary (Annual)
According to Astellas Pharma's latest annual financial reports:
- The company has reported a gross profit of 1.31T, indicating the amount earned after deducting the cost of goods sold (COGS) from revenue. The gross profit margin is 81.76%, with a year-over-year growth of 6.58%.
- Astellas Pharma's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 195.34B. The EBITDA margin stands at 12.18%, showing a growth of -18.76% compared to the previous year.
- The operating income, representing the profit from business operations before taxes and interest, stands at 124.61B. The operating margin is 7.77%, with a year-over-year growth of -6.33%.
- The net income, which shows the company's total earnings or profit after all expenses, is 17.05B. The net profit margin is 1.06%, demonstrating a growth of -82.73% from the previous year.
These metrics provide a comprehensive overview of Astellas Pharma's profitability and operational efficiency over the past year.
Gross Profit
$1.31T
Gross Profit Margin (2023)
81.76%
EBITDA
$195.34B
EBITDA Margin
12.18%
Operating Income (2023)
$124.61B
Operating Margin
7.77%
Net Income
$17.05B
Net Profit Margin
1.06%
Historical Gross Profit
Historical Gross Profit Margin
Historical Gross Profit Growth
Historical EBITDA
Historical EBITDA Margin
Historical EBITDA Growth
Historical Operating Income
Historical Operating Profit Margin
Historical Operating Income Growth
Historical Net Income
Historical Net Profit Margin
Historical Net Income Growth
Astellas Pharma Historical Profit Metrics
Astellas Pharma Historical Profits
The table below shows various profit metrics for each year, with the latest data available for the last fiscal year 2023.
| Year | Gross Profit | Gross Profit Growth | Operating Income | Operating Income Growth | Net Income | Net Income Growth | EBITDA | EBITDA Growth |
|---|---|---|---|---|---|---|---|---|
| 2023 | $1.31T | 6.58% | $124.61B | -6.33% | $17.05B | -82.73% | $195.34B | -18.76% |
| 2022 | $1.23T | 17.94% | $133.03B | -14.55% | $98.71B | -20.45% | $240.46B | -0.24% |
| 2021 | $1.04T | 3.96% | $155.69B | 14.43% | $124.09B | 2.90% | $241.03B | 9.64% |
| 2020 | $1.00T | -2.02% | $136.05B | -44.24% | $120.59B | -38.29% | $219.83B | -30.52% |
| 2019 | $1.02T | 0.97% | $243.99B | 0.03% | $195.41B | -12.08% | $316.41B | 0.86% |
| 2018 | $1.01T | 0.82% | $243.91B | 14.37% | $222.26B | 34.97% | $313.73B | 10.36% |
| 2017 | $1.01T | 1.50% | $213.26B | -18.24% | $164.68B | -24.70% | $284.28B | -18.05% |
| 2016 | $991.16B | -4.43% | $260.83B | 4.76% | $218.70B | 12.91% | $346.90B | 4.42% |
| 2015 | $1.04T | 13.46% | $248.99B | 34.11% | $193.69B | 42.57% | $332.21B | 29.96% |
| 2014 | $914.06B | 12.95% | $185.66B | 58.95% | $135.86B | 49.50% | $255.62B | 36.89% |
| 2013 | $809.28B | 18.75% | $116.81B | -24.09% | $90.87B | 9.68% | $186.74B | 4.50% |
| 2012 | $681.48B | 4.72% | $153.87B | 16.99% | $82.85B | 5.91% | $178.70B | -7.26% |
| 2011 | $650.75B | -1.10% | $131.52B | 10.35% | $78.23B | 15.64% | $192.70B | 13.92% |
| 2010 | $657.98B | -4.03% | $119.18B | -36.06% | $67.65B | -44.67% | $169.16B | -28.10% |
| 2009 | $685.64B | -2.23% | $186.41B | -25.55% | $122.26B | -28.50% | $235.27B | -23.02% |
| 2008 | $701.27B | 1.16% | $250.39B | -9.25% | $170.99B | -3.64% | $305.63B | -0.05% |
| 2007 | $693.24B | 8.90% | $275.90B | 44.82% | $177.44B | 35.15% | $305.77B | 24.26% |
| 2006 | $636.56B | 4.98% | $190.51B | -1.30% | $131.29B | 26.65% | $246.08B | 2.98% |
| 2005 | $606.37B | 98.24% | $193.02B | 77.26% | $103.66B | 207.44% | $238.95B | 168.95% |
| 2004 | $305.88B | -9.35% | $108.89B | 7.85% | $33.72B | -43.86% | $88.84B | -31.08% |
Related Metrics
Explore detailed financial metrics and analysis for 4503.T.